Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New World Arenaviruses

Amanat, Fatima; Duehr, James; Oestereich, Lisa; Hastie, Kathryn M.; Saphire, Erica Ollmann; Krammer, Florian

doi:10.1128/msphere.00189-18

Cited by 42 publications

(50 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recombinant proteins were produced using the well-established baculovirus expression system and this system has been published in detail in refs. [20][21][22] , including a video guide. Recombinant proteins were also produced in Expi293F cells (Thermo Fisher Scientific) by transfections of these cells with purified DNA using an ExpiFectamine 293 Transfection Kit (Thermo Fisher Scientific).…”

Section: Methodsmentioning

confidence: 99%

A serological assay to detect SARS-CoV-2 seroconversion in humans

Amanat

Stadlbauer

Strohmeier

et al. 2020

Nat Med

Self Cite

1,816

1,665

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

A serological assay to detect SARS-CoV-2 seroconversion in humans

Amanat

Stadlbauer

Strohmeier

et al. 2020

Nat Med

Self Cite

1,816

1,665

View full text Add to dashboard Cite

“…The GP is also regarded as the primary immunogen for LASV vaccine development [36] because vaccines expressing LASV GP conferred a higher level of protection than those expressing LASV NP only [23,47]. GP1 is the most variable subunit, while the GP2 is the most conserved subunit among mammarenaviruses [14,54,55]. Synonymous single nucleotide variations (SNV) were found in similar rates in both subunits of the GP and most non-synonymous SNVs were found in the GP1 subunit among intra-host LASV strains [12].…”

Section: Gp Variation Among Lasv Lineagesmentioning

confidence: 99%

Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development

Ibukun

2020

Viruses

View full text Add to dashboard Cite

Lassa virus (LASV), which causes considerable morbidity and mortality annually, has a high genetic diversity across West Africa. LASV glycoprotein (GP) expresses this diversity, but most LASV vaccine candidates utilize only the Lineage IV LASV Josiah strain GP antigen as an immunogen and homologous challenge with Lineage IV LASV. In addition to the sequence variation amongst the LASV lineages, these lineages are also distinguished in their presentations. Inter-lineage variations within previously mapped B-cell and T-cell LASV GP epitopes and the breadth of protection in LASV vaccine/challenge studies were examined critically. Multiple alignments of the GP primary sequence of strains from each LASV lineage showed that LASV GP has diverging degrees of amino acid conservation within known epitopes among LASV lineages. Conformational B-cell epitopes spanning different sites in GP subunits were less impacted by LASV diversity. LASV GP diversity should influence the approach used for LASV vaccine design. Expression of LASV GP on viral vectors, especially in its prefusion configuration, has shown potential for protective LASV vaccines that can overcome LASV diversity. Advanced vaccine candidates should demonstrate efficacy against all LASV lineages for evidence of a pan-LASV vaccine.

show abstract

“…However, reported nAbs rarely possess crossneutralization against them. MAbs targeting sequence-conserved GP2 are considered very promising, while antibodies that cross-react with both NW and Old World arenaviruses neutralize neither (Amanat et al, 2018). NAbs for JUNV simply targeting GP1 have not been reported to have cross-neutralization capabilities against the five arenaviruses except for one elicited by Candid#1 that neutralizes both JUNV and MACV with varying efficiency in vitro (Clark et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

Development of horse neutralizing immunoglobulin and immunoglobulin fragments against Junín virus

Pan

Wang

et al. 2020

Antiviral Research

View full text Add to dashboard Cite

Argentine haemorrhagic fever (AHF) is a rodent-borne disease with a lethality as high as~30%, which is caused by the New World arenavirus, Junín virus (JUNV). It was once a major epidemic in South America and puts millions of people in Argentina at risk. Here, we aimed to develop horse antibodies or antibody fragments against JUNV. Before preparing the horse antibodies, a strategy to efficiently generate horse antisera was established based on comparisons among immunogens and immunization methods in both mice and horses. Antisera against JUNV were finally obtained by vaccinating horses with vesicular stomatitis virus pseudotypes bearing JUNV GP. The horse antibodies IgG and F(ab') 2 were subsequently demonstrated to effectively neutralize vesicular stomatitis virus pseudotypes bearing JUNV GP and to show some cross-neutralization against pathogenic New World arenaviruses. Further research revealed that Asp123 on GP1 is an important site for the binding of antibodies targeting mainly JUNV GP1 for neutralization. Collectively, this study presents an efficient strategy to develop horse antisera against JUNV and provides GP1-specific horse antibodies as potential therapeutics for AHF.

show abstract

Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New World Arenaviruses

Cited by 42 publications

References 43 publications

A serological assay to detect SARS-CoV-2 seroconversion in humans

A serological assay to detect SARS-CoV-2 seroconversion in humans

Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development

Development of horse neutralizing immunoglobulin and immunoglobulin fragments against Junín virus

Contact Info

Product

Resources

About